乌干达东部艾滋病毒感染者和糖尿病患者的血糖控制:一个横截面研究
1Department of Community Health and Epidemiology, Kenyatta University, Uganda.
Nigerian medical journal : journal of the Nigeria Medical Association
|December 31, 2025
概括
低血糖控制影响了乌干达超过一半的艾滋病毒感染者和糖尿病患者. 高等教育与较高的HbA1c水平有显著的关联,表明需要有针对性的干预措施.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 内分泌学 在内分泌学.
背景情况:
- 低血糖控制是非洲,特别是乌干达艾滋病毒感染者 (PLWH) 和糖尿病患者的主要公共卫生挑战.
- 艾滋病毒和糖尿病的双重诊断与管理成本增加和健康结果较差有关.
- 了解基线血糖控制在这个人群中对于有效的公共卫生策略至关重要.
研究的目的:
- 确定乌干达东部艾滋病毒感染者和糖尿病患者血糖控制不良的流行情况.
- 在这个特定的患者群体中确定与低血糖控制相关的因素.
- 在PLWH中为改善糖尿病管理提供有针对性的干预信息.
主要方法:
- 采用了一种定量,横截面的分析研究设计.
- 从Mbale和Soroti区域推医院的257名参与者收集数据,使用电子问卷.
- 使用Finecare自动化HbA1c分析仪测量HbA1c水平,并使用多变量逻辑回归分析数据.
主要成果:
- 超过一半的参与者 (52.9%) 的HbA1c水平高于7%.
- 与血糖控制不佳积极相关的因素包括50岁以上,有三个以上的孩子和高等教育.
- 在对混因素进行调整后,高等教育是唯一具有统计意义的因素 (aPOR 3.9,p=0.037).
结论:
- 在乌干达的Mbale和Soroti医院,艾滋病毒感染者和糖尿病患者中,血糖控制不良的患病率很高 (52.9%).
- 50岁以上的年龄,有孩子和高等教育与低血糖控制有关.
- 对于这些风险群体,建议进行常规的HbA1c测试和基于证据的管理.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Diabetes: Management and Pharmacotherapy
844
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
844
Oral Hypoglycemic Agents: Biguanides and Glitazones
559
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560


